Fujifilm Irvine Scientific Celebrates 50 Years of Providing Cell Culture Media Products and Services
Originally established in the 1970s as a fetal bovine serum supplier, Fujifilm Irvine Scientific continuously proved its strength in the cell culture solutions space.
On May 11, 2021, Fujifilm Irvine Scientific celebrated 50 years of providing cell culture media products and services.
Originally established in the 1970s as a fetal bovine serum supplier, the company continuously proved its strength in the cell culture solutions space by modernizing embryo culture with commercially available media for in vitro fertilization clinics worldwide and by bringing chemically defined media to biotherapeutic manufacturers, Fujifilm Irvine Scientific said in a company press release. Recently, the company introduced products better suited for cell culture-based vaccine production, and advanced cell and gene therapy applications.
“We have reflected on our trailblazing history and many contributions over the last five decades. Our 50th year coincided with unprecedented challenges from the COVID-19 pandemic,” said Yutaka Yamaguchi, CEO and chairman of the board, Fujifilm Irvine Scientific, in the press release. “We are grateful for the dedication and commitment shown by our employees to uphold our standards of delivering the highest quality products and service under these difficult conditions. We are also humbled by the extraordinary efforts of the community we serve in the fight against the virus and honored that our customers trust Fujifilm Irvine Scientific to provide the critical cell culture media needed to manufacture lifesaving therapies and vaccines, and to support medical applications. We are inspired to continue our mission to improve health through innovation, partnership, and service for the next 50 years.”
Source: Fujifilm Irvine Scientific
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
